Literature DB >> 9532813

[Safety and feasibility of dobutamine-atropine stress echocardiography].

W Mathias Júnior1, L P Beneti, F C dos Santos, R Duprat, A Beraldo, M A Gil, J L Andrade, E Martinez.   

Abstract

PURPOSE: To study the safety and feasibility of dobutamine-atropine stress echocardiography (DASE) in patients with known or suspected coronary artery disease.
METHODS: There were 3,000 DASE that were studied in a prospective fashion. All symptoms and side effects were stored in a data base format.
RESULTS: Major test-related complications observed included one case of myocardial infarction, four cases of sustained ventricular tachycardia and five cases of atropine intoxication. There was no death or ventricular fibrillation as a direct or indirect consequence of the test. The infusion protocol allowed to us to examine patients using beta blockers, and led to 95% feasibility.
CONCLUSION: DASE is a safe and feasible method for the study of patients with suspected or known coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9532813

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  2 in total

1.  Dobutamine Stress Echocardiography Safety in Chagas Disease Patients.

Authors:  Daniela do Carmo Rassi; Marcelo Luiz Campos Vieira; Rogerio Gomes Furtado; Fabio de Paula Turco; Luciano Henrique Melato; Viviane Tiemi Hotta; Colandy Godoy de Oliveira Nunes; Luiz Rassi; Salvador Rassi
Journal:  Arq Bras Cardiol       Date:  2017-01-16       Impact factor: 2.000

2.  Safety of SF6(SonoVue®) Contrast Agent on Pharmacological Stress Echocardiogram.

Authors:  Rogerio Gomes Furtado; Daniela do Carmo Rassi; Luciano Henrique Melato; Ana Caroline Reinaldo de Oliveira; Paula Meneses Nunes; Priscila Elias Baccelli; Sara Camila de Oliveira Santos; Victor Emanuel Santos; Luiz Rassi Junior; Colandy Godoy Nunes
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.